#1 Clinical Trials Search in Europe

Dapagliflozin

Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is being extensively studied in clinical trials for its potential benefits in treating various medical conditions. Originally developed for type 2 diabetes management, researchers are now exploring its effects on heart, kidney, and lung health. This article summarizes key findings from recent clinical trials investigating dapagliflozin’s efficacy and safety across different patient populations.

Table of Contents

What is Dapagliflozin?

Dapagliflozin is a medication primarily used to treat type 2 diabetes mellitus. It belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. This medication is also known by its brand names Farxiga, Forxiga, and BMS-512148[1]. Dapagliflozin works in a unique way to help control blood sugar levels in people with diabetes.

How Dapagliflozin Works

Dapagliflozin works by inhibiting the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose (sugar) from the urine back into the bloodstream. By blocking SGLT2, dapagliflozin causes more glucose to be excreted in the urine, which helps lower blood sugar levels[2]. This mechanism of action is different from other diabetes medications that work by affecting insulin production or sensitivity.

Conditions Treated by Dapagliflozin

While primarily used for type 2 diabetes, research has shown that dapagliflozin may be beneficial for several other conditions:

  • Type 2 Diabetes Mellitus: This is the primary use of dapagliflozin. It helps control blood sugar levels in adults with type 2 diabetes[3].
  • Chronic Kidney Disease: Dapagliflozin may help slow the progression of kidney function decline in patients with chronic kidney disease[2].
  • Heart Failure: Studies are investigating the use of dapagliflozin in patients with heart failure, including those who have undergone procedures like transcatheter aortic valve implantation (TAVI)[4].
  • Pulmonary Arterial Hypertension: Research is ongoing to determine if dapagliflozin can improve exercise capacity and heart function in patients with pulmonary arterial hypertension[5].
  • Tricuspid Regurgitation: A study is examining whether dapagliflozin can help improve heart function in patients with severe tricuspid regurgitation, a condition affecting the tricuspid valve in the heart[6].

Dosage and Administration

Dapagliflozin is typically taken orally as a tablet. The most common dosage is 10 mg once daily[3]. However, the exact dosage may vary depending on the condition being treated and individual patient factors. It’s important to take dapagliflozin exactly as prescribed by your healthcare provider.

Benefits and Effectiveness

Dapagliflozin has shown several benefits in clinical studies:

  • Improved blood sugar control in patients with type 2 diabetes[3]
  • Potential reduction in the risk of hospitalization for heart failure[4]
  • Possible slowing of kidney function decline in patients with chronic kidney disease[2]
  • Potential improvements in exercise capacity and heart function in patients with certain heart conditions[5]

Ongoing Research and Potential New Uses

Researchers are continuously studying dapagliflozin to understand its full potential. Some areas of ongoing research include:

  • Use in patients with kidney transplants to potentially improve kidney function[2]
  • Effects on heart function and exercise capacity in patients with pulmonary arterial hypertension[5]
  • Potential benefits for patients with severe tricuspid regurgitation[6]
  • Use in pediatric patients with type 2 diabetes[7]

Side Effects and Safety Considerations

Like all medications, dapagliflozin can cause side effects. Common side effects may include:

  • Increased urination
  • Urinary tract infections
  • Genital yeast infections
  • Low blood pressure
  • Changes in kidney function

In rare cases, more serious side effects can occur. These may include severe urinary tract infections, diabetic ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones), and kidney problems[8].

It’s important to discuss all potential risks and benefits with your healthcare provider before starting dapagliflozin. They will consider your individual health status and other medications you may be taking to determine if dapagliflozin is right for you.

Condition Studied Key Findings/Objectives Dosage Trial Duration
Type 2 Diabetes Evaluating pharmacokinetics, pharmacodynamics, safety, and tolerability in healthy subjects 0.001 mg to 2.5 mg 2 days
Atrial Fibrillation Assessing effect on recurrence of atrial tachyarrhythmia after catheter ablation 10 mg daily 3 months treatment, 1 year follow-up
Chronic Kidney Disease Investigating protective effects on kidney function after heart procedures 10 mg daily 1 month
Heart Failure after TAVI Evaluating benefits in patients with severe aortic stenosis after valve implantation 10 mg daily 12 months
Type 2 Diabetes with Impaired Renal Function Studying natriuretic effect in patients with impaired kidney function 10 mg daily 2 weeks
Severe Tricuspid Regurgitation Assessing efficacy on right ventricular remodeling and tricuspid regurgitation 10 mg daily 48 weeks
Pulmonary Arterial Hypertension Investigating effects on exercise capacity and hemodynamics 10 mg daily 3 months

FAQ

  • What is dapagliflozin and how does it work? Dapagliflozin is a medication that belongs to a class called SGLT2 inhibitors. It works by helping the kidneys remove excess sugar from the body through urine. This helps lower blood sugar levels in people with type 2 diabetes.
  • What conditions are being studied with dapagliflozin in clinical trials? Recent clinical trials are exploring dapagliflozin's potential benefits in various conditions, including type 2 diabetes, chronic kidney disease, heart conditions like atrial fibrillation and tricuspid regurgitation, and pulmonary arterial hypertension.
  • Is dapagliflozin safe for people with kidney problems? Several trials are specifically studying dapagliflozin in people with chronic kidney disease. These studies aim to determine if dapagliflozin can help slow the decline of kidney function and reduce protein in the urine. However, the safety and appropriate dosing for people with kidney problems are still being evaluated.
  • What are some potential side effects of dapagliflozin? Common side effects may include urinary tract infections, genital yeast infections, and increased urination. Some trials are monitoring for specific side effects like hypoglycemia (low blood sugar), hypotension (low blood pressure), and changes in kidney function.
  • How long do clinical trials for dapagliflozin typically last? The duration of clinical trials for dapagliflozin varies depending on the study's goals. Some trials last a few weeks to assess short-term effects, while others may continue for several months or even years to evaluate long-term safety and efficacy.

Ongoing Clinical Trials on Dapagliflozin

  • Study on Using Dapagliflozin, Semaglutide, and Finerenone to Prevent Heart and Kidney Complications in Patients with Type 2 Diabetes

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark Spain

  • Study on Dapagliflozin for Heart and Kidney Health in Adults After ICU Discharge with Heart or Kidney Issues

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Empagliflozin and Dapagliflozin for Patients Hospitalized with Acute Heart Failure

    Recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on Dapagliflozin for Patients with Chronic Right Heart Failure

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects of Dapagliflozin on Kidney Health in Patients with Chronic Kidney Disease After Kidney Transplantation

    Recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany The Netherlands Spain

  • Study on the Effects of Semaglutide, Dapagliflozin, and Metformin in Patients with Coronary Artery Disease and Prediabetes

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study of Dapagliflozin to Preserve Function in Transplanted Kidneys

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Czechia Finland France Germany +9

Glossary

  • SGLT2 inhibitor: A class of medications that work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in urine and lowered blood sugar levels.
  • Chronic Kidney Disease (CKD): A condition characterized by gradual loss of kidney function over time, often associated with diabetes, high blood pressure, or other health issues.
  • Atrial Fibrillation (AF): An irregular and often rapid heart rhythm that can lead to blood clots in the heart.
  • Tricuspid Regurgitation (TR): A heart valve condition where the tricuspid valve doesn't close properly, allowing blood to flow back into the right atrium.
  • Pulmonary Arterial Hypertension (PAH): High blood pressure in the arteries of the lungs, which can lead to heart failure.
  • eGFR: Estimated Glomerular Filtration Rate, a test used to check how well the kidneys are working.
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney damage.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and therapeutic effects.
  • Cardioversion: A medical procedure used to restore a normal heart rhythm for people with certain types of abnormal heartbeats.

References

  1. https://clinicaltrials.gov/study/NCT01135446
  2. https://clinicaltrials.gov/study/NCT04743453
  3. https://clinicaltrials.gov/study/NCT05418946
  4. https://clinicaltrials.gov/study/NCT04696185
  5. https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-patients-with-pulmonary-arterial-hypertension-to-improve-exercise-capacity-and-heart-function/
  6. https://clinicaltrials.gov/study/NCT05686616
  7. https://clinicaltrials.gov/study/NCT01525238
  8. https://clinicaltrials.gov/study/NCT05225077